Viromed Medical AG completes a €4.5 m capital increase

Viromed Medical AG, the German‑based health‑care company behind products such as ViroCAP and PulmoPlas, announced on 26 October 2026 that it had successfully executed a capital‑raising transaction. The measure involved the issuance of 450,000 new registered no‑par value shares, each priced at €4.50. The gross proceeds from the placement amounted to €2,025,000 before any associated costs.

Exclusion of subscription rights

Unlike a typical rights issue, the company chose to exclude existing shareholders from participating in the placement. This decision, reported in several market‑data feeds (nwr.eqs‑cockpit.com, www.finanzen.net , www.eqs-news.com ), was made to ensure that the cash infusion would be achieved without diluting current owners. The move is consistent with the company’s strategy of preserving shareholder value while securing the capital needed for expansion.

Financial impact

The proceeds are earmarked for the continued development and global distribution of Viromed’s medical products, including dermatology and wound‑care solutions and respiratory therapies. By injecting fresh equity, the company strengthens its balance sheet, improving liquidity and enabling accelerated research, regulatory approvals, and market penetration.

With a market capitalization of approximately €99 million as of the close on 27 October 2026, the capital increase represents a modest but significant percentage of the company’s equity base. The move is expected to reinforce investor confidence, particularly after the recent volatility observed in the company’s share price—rising from a 52‑week low of €3.18 to a high of €8.45 in February, before settling at €4.66 at the close of the previous trading day.

Forward outlook

Viromed’s leadership has highlighted that the additional capital will accelerate the commercialization of its flagship products and support entry into new therapeutic areas. The company’s focus on both prescription‑grade and over‑the‑counter health products positions it well to capture a broad segment of the healthcare market.

Investors will be watching the company’s quarterly reporting for indications of how the new funds are deployed and whether they translate into revenue growth and margin expansion. The successful completion of the capital increase, coupled with Viromed’s product pipeline, suggests that the firm is poised to maintain its trajectory in a competitive sector.